150 related articles for article (PubMed ID: 37046833)
1. Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer.
Arentz G; Mittal P; Klingler-Hoffmann M; Condina MR; Ricciardelli C; Lokman NA; Kaur G; Oehler MK; Hoffmann P
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046833
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
Kim SI; Hwangbo S; Dan K; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
Mol Cell Proteomics; 2023 Mar; 22(3):100502. PubMed ID: 36669591
[TBL] [Abstract][Full Text] [Related]
3. ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome.
Wang W; Lokman NA; Noye TM; Macpherson AM; Oehler MK; Ricciardelli C
Cancer Drug Resist; 2021; 4(2):485-502. PubMed ID: 35582032
[No Abstract] [Full Text] [Related]
4. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
5. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
6. High
Li XF; Zhang HB; Huo Y
J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
[TBL] [Abstract][Full Text] [Related]
7. Promoter Methylation of the
Li XF; Sun HY; Hua T; Zhang HB; Tian YJ; Li Y; Kang S
Front Oncol; 2021; 11():659254. PubMed ID: 34268111
[TBL] [Abstract][Full Text] [Related]
8. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.
Bateman NW; Jaworski E; Ao W; Wang G; Litzi T; Dubil E; Marcus C; Conrads KA; Teng PN; Hood BL; Phippen NT; Vasicek LA; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP
J Proteome Res; 2015 Apr; 14(4):1900-10. PubMed ID: 25748058
[TBL] [Abstract][Full Text] [Related]
9. Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells.
Weiland F; Arentz G; Klingler-Hoffmann M; McCarthy P; Lokman NA; Kaur G; Oehler MK; Hoffmann P
J Proteome Res; 2016 Nov; 15(11):4073-4081. PubMed ID: 27569743
[TBL] [Abstract][Full Text] [Related]
10. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
13. Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma.
Kim SI; Jung M; Dan K; Lee S; Lee C; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224886
[TBL] [Abstract][Full Text] [Related]
14. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
15. Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry.
Huh S; Kang C; Park JE; Nam D; Kim SI; Seol A; Choi K; Hwang D; Yu MH; Chung HH; Lee SW; Kang UB
J Proteome Res; 2022 Sep; 21(9):2146-2159. PubMed ID: 35939567
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
[TBL] [Abstract][Full Text] [Related]
18. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
20. Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues.
Penick ER; Bateman NW; Rojas C; Magana C; Conrads K; Zhou M; Hood BL; Wang G; Parikh N; Huang Y; Darcy KM; Casablanca Y; Mhawech-Fauceglia P; Conrads TP; Maxwell GL
Clin Proteomics; 2022 Oct; 19(1):35. PubMed ID: 36195845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
